CNS Pharmaceuticals, Inc. (CNSP)
NASDAQ: CNSP · Real-Time Price · USD
1.090
+0.050 (4.81%)
At close: Apr 25, 2025, 4:00 PM
1.120
+0.030 (2.75%)
After-hours: Apr 25, 2025, 6:54 PM EDT
Company Description
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors.
The company’s lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.
CNS Pharmaceuticals, Inc. has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D.
Anderson Cancer Center, as well as a collaboration and asset purchase agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
CNS Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2017 |
| IPO Date | Nov 8, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | John Climaco |
Contact Details
Address: 2100 West Loop South, Suite 900 Houston, Texas 77027 United States | |
| Phone | 800 946 9185 |
| Website | cnspharma.com |
Stock Details
| Ticker Symbol | CNSP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001729427 |
| CUSIP Number | 18978H409 |
| ISIN Number | US18978H4092 |
| Employer ID | 82-2318545 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John Michael Climaco Esq., J.D. | Chief Executive Officer, President and Director |
| Christopher S. Downs CPA, CTP, FP&A | Chief Financial Officer |
| Dr. Sandra L. Silberman M.D., Ph.D. | Chief Medical Officer |
| Dr. Waldemar Priebe Ph.D. | Founder |
| Dr. Donald H. Picker Ph.D. | Chief Science Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 14, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Apr 9, 2025 | 8-K | Current Report |
| Apr 7, 2025 | DRS | [Cover] Draft Registration Statement |
| Mar 31, 2025 | 8-K | Current Report |
| Mar 31, 2025 | 10-K | Annual Report |
| Mar 20, 2025 | 424B5 | Filing |
| Mar 20, 2025 | 8-K | Current Report |
| Feb 21, 2025 | 8-K | Current Report |
| Jan 3, 2025 | 8-K | Current Report |
| Dec 11, 2024 | 8-K | Current Report |